Literature DB >> 20688189

High-content imaging for automated determination of host-cell infection rate by the intracellular parasite Trypanosoma cruzi.

L L Nohara1, C Lema, J O Bader, R J Aguilera, I C Almeida.   

Abstract

Chagas disease affects 8-11 million people, mostly in Latin America. Sequelae include cardiac, peripheral nervous and/or gastrointestinal disorders, thus placing a large economic and social burden on endemic countries. The pathogenesis and the evolutive pattern of the disease are not fully clarified. Moreover, available drugs are partially effective and toxic, and there is no vaccine. Therefore, there is an urgent need to speed up basic and translational research in the field. Here, we applied automated high-content imaging to generate multiparametric data on a cell-by-cell basis to precisely and quickly determine several parameters associated with in vitro infection of host cell by Trypanosoma cruzi, the causative agent of Chagas disease. Automated and manual quantifications were used to determine the percentage of T. cruzi-infected cells in a 96-well microplate format and the data generated was statistically evaluated. Most importantly, this automated approach can be widely applied for discovery of potential drugs as well as molecular pathway elucidation not only in T. cruzi but also in other human intracellular pathogens.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20688189      PMCID: PMC2964385          DOI: 10.1016/j.parint.2010.07.007

Source DB:  PubMed          Journal:  Parasitol Int        ISSN: 1383-5769            Impact factor:   2.230


  37 in total

Review 1.  The life cycle of Trypanosoma cruzi revisited.

Authors:  K M Tyler; D M Engman
Journal:  Int J Parasitol       Date:  2001-05-01       Impact factor: 3.981

Review 2.  A critical review on Chagas disease chemotherapy.

Authors:  José Rodriques Coura; Solange L de Castro
Journal:  Mem Inst Oswaldo Cruz       Date:  2002-01       Impact factor: 2.743

3.  Detection of mycoplasma contaminations.

Authors:  Cord C Uphoff; Hans G Drexler
Journal:  Methods Mol Biol       Date:  2005

4.  Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Authors:  Juan C Engel; Kenny K H Ang; Steven Chen; Michelle R Arkin; James H McKerrow; Patricia S Doyle
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 5.  Cell signalling and Trypanosoma cruzi invasion.

Authors:  Barbara A Burleigh; Aaron M Woolsey
Journal:  Cell Microbiol       Date:  2002-11       Impact factor: 3.715

6.  Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives.

Authors:  L Lauria-Pires; M S Braga; A C Vexenat; N Nitz; A Simões-Barbosa; D L Tinoco; A R Teixeira
Journal:  Am J Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.345

Review 7.  Use of polymerase chain reaction to diagnose the fifth reported US case of autochthonous transmission of Trypanosoma cruzi, in Tennessee, 1998.

Authors:  B L Herwaldt; M J Grijalva; A L Newsome; C R McGhee; M R Powell; D G Nemec; F J Steurer; M L Eberhard
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

8.  Host cell actin polymerization is required for cellular retention of Trypanosoma cruzi and early association with endosomal/lysosomal compartments.

Authors:  Aaron M Woolsey; Barbara A Burleigh
Journal:  Cell Microbiol       Date:  2004-09       Impact factor: 3.715

9.  Inhibition of in vitro intracellular growth of Trypanosoma cruzi by dicationic compounds.

Authors:  Edwin C Rowland; Deborah Moore-Lai; John R Seed; Chad E Stephens; David W Boykin
Journal:  J Parasitol       Date:  2003-10       Impact factor: 1.276

10.  Killing in vitro of Trypanosoma cruzi by macrophages from mice immunized with T. cruzi or BCG, and absence of cross-immunity on challege in vivo.

Authors:  R Hoff
Journal:  J Exp Med       Date:  1975-08-01       Impact factor: 14.307

View more
  18 in total

1.  Metal-drug synergy: new ruthenium(II) complexes of ketoconazole are highly active against Leishmania major and Trypanosoma cruzi and nontoxic to human or murine normal cells.

Authors:  Eva Iniguez; Antonio Sánchez; Miguel A Vasquez; Alberto Martínez; Joanna Olivas; Aaron Sattler; Roberto A Sánchez-Delgado; Rosa A Maldonado
Journal:  J Biol Inorg Chem       Date:  2013-07-24       Impact factor: 3.358

2.  Evaluation of α,β-unsaturated ketones as antileishmanial agents.

Authors:  Miguel A Vasquez; Eva Iniguez; Umashankar Das; Stephen M Beverley; Linda J Herrera; Jonathan R Dimmock; Rosa A Maldonado
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

3.  Searching for new chemotherapies for tropical diseases: ruthenium-clotrimazole complexes display high in vitro activity against Leishmania major and Trypanosoma cruzi and low toxicity toward normal mammalian cells.

Authors:  Alberto Martínez; Teresia Carreon; Eva Iniguez; Atilio Anzellotti; Antonio Sánchez; Marina Tyan; Aaron Sattler; Linda Herrera; Rosa A Maldonado; Roberto A Sánchez-Delgado
Journal:  J Med Chem       Date:  2012-04-09       Impact factor: 7.446

4.  Ruthenium-Clotrimazole complex has significant efficacy in the murine model of cutaneous leishmaniasis.

Authors:  Eva Iniguez; Armando Varela-Ramirez; Alberto Martínez; Caresse L Torres; Roberto A Sánchez-Delgado; Rosa A Maldonado
Journal:  Acta Trop       Date:  2016-09-30       Impact factor: 3.112

5.  In Vitro and In Vivo Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors.

Authors:  Felipe Rodriguez; Sarah F John; Eva Iniguez; Sebastian Montalvo; Karina Michael; Lyndsey White; Dong Liang; Omonike A Olaleye; Rosa A Maldonado
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

6.  Differential nuclear staining assay for high-throughput screening to identify cytotoxic compounds.

Authors:  Carolina Lema; Armando Varela-Ramirez; Renato J Aguilera
Journal:  Curr Cell Biochem       Date:  2011-09-12

7.  An image-based algorithm for precise and accurate high throughput assessment of drug activity against the human parasite Trypanosoma cruzi.

Authors:  Seunghyun Moon; Jair L Siqueira-Neto; Carolina Borsoi Moraes; Gyongseon Yang; Myungjoo Kang; Lucio H Freitas-Junior; Michael A E Hansen
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

Review 8.  High throughput screening for anti-Trypanosoma cruzi drug discovery.

Authors:  Julio Alonso-Padilla; Ana Rodríguez
Journal:  PLoS Negl Trop Dis       Date:  2014-12-04

9.  Automated high-content assay for compounds selectively toxic to Trypanosoma cruzi in a myoblastic cell line.

Authors:  Julio Alonso-Padilla; Ignacio Cotillo; Jesús L Presa; Juan Cantizani; Imanol Peña; Ana I Bardera; Jose J Martín; Ana Rodriguez
Journal:  PLoS Negl Trop Dis       Date:  2015-01-23

10.  Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity.

Authors:  Bianca Zingales; Michael A Miles; Carolina B Moraes; Alejandro Luquetti; Felipe Guhl; Alejandro G Schijman; Isabela Ribeiro
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-08-22       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.